Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Phathom Pharmaceuticals ( (PHAT) ) just unveiled an announcement.
On June 3, 2025, Phathom Pharmaceuticals held its Annual Meeting of Stockholders, where key decisions were made regarding the election of directors, ratification of the accounting firm, and executive compensation. The stockholders elected Class III directors, ratified Ernst & Young LLP as the accounting firm for 2025, approved executive compensation, and decided to hold annual votes on executive compensation, aligning with the board’s recommendations.
The most recent analyst rating on (PHAT) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on Phathom Pharmaceuticals stock, see the PHAT Stock Forecast page.
Spark’s Take on PHAT Stock
According to Spark, TipRanks’ AI Analyst, PHAT is a Neutral.
Phathom Pharmaceuticals’ overall stock score reflects a challenging financial position with significant revenue growth offset by high net losses and financial instability. Positive developments in corporate events and strategic initiatives provide some optimism, but technical and valuation metrics indicate caution.
To see Spark’s full report on PHAT stock, click here.
More about Phathom Pharmaceuticals
Phathom Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on developing and commercializing novel treatments for gastrointestinal diseases.
Average Trading Volume: 2,447,672
Technical Sentiment Signal: Buy
Current Market Cap: $622.7M
For a thorough assessment of PHAT stock, go to TipRanks’ Stock Analysis page.